> Antigen, Antibodies, ELISA, Western Blot > Primary Antibody > Polyclonal Antibodies > OAS3 / p100 Antibody (aa1070-1087)Brand |
Leading Biology | Catalog Number |
APR02184G |
Product Type |
Polyclonal Antibodies | Field of Research |
|
Product Overview |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality OAS3 / p100 Antibody (aa1070-1087).
|
||
Molecular Weight |
121kDa
|
||
Cellular Localization |
Antigen Cellular Localization:
Cytoplasm. Nucleus.
|
||
Host |
Rabbit
|
||
Species Reactivity |
Human
|
||
Target |
Amino acids 1070 to 1087 of human OAS3
|
||
GeneID |
|||
UniProt ID |
|||
Function |
Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes preferentially dimers of 2'-5'- oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. Displays antiviral activity against Chikungunya virus (CHIKV), Dengue virus, Sindbis virus (SINV) and Semliki forest virus (SFV).
|
||
Summary |
Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes preferentially dimers of 2'-5'- oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. Displays antiviral activity against Chikungunya virus (CHIKV), Dengue virus, Sindbis virus (SINV) and Semliki forest virus (SFV).
|
||
Form |
Liquid |
||
Storage & Stability |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
Applications |
WB, IHC-P, E
|
||
Dilution |
ELISA (1:1000), IHC-P (10 μg/ml), WB (1:100-1:500)
|
||
Images |
|
||
Specification |
|||
Quantity |
|
||
| Select | Brand | Catalog No. | Product Name | Pack Size | Type | Field of Research | Specification | Quantity | Price(USD) | |
| 1 | Leading Biology | APR03440G | ITGA11 Antibody (N-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 2 | Leading Biology | APR04537G | CMIP Antibody (C-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 3 | Leading Biology | APR12422G | Human H4 Histamine Receptor (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
$695.00 | Add Ask | ||
| 4 | Leading Biology | APR03844G | UBE2W Antibody (C-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 5 | Leading Biology | APR04349G | HECTD2 Antibody (N-term) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask | ||
| 6 | Leading Biology | APR03502G | IGHG1 Antibody (Center) | 100 μl | Polyclonal Antibodies |
|
$495.00 | Add Ask |
Leading Biology Inc.
2600 Hilltop DR, Building G, B Suite C138
Richmond, CA, 94806
Tel: 1-661-524(LBI)-0262
Email: info@leadingbiology.com
You have 0 item in your cart
You have 0 item in your inquiry list
